The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a more substantial decrease in body size and improve metabolic function, partic